Mostra risultati da 1 a 20 di 28
successivo >
Titolo Data di pubblicazione Autore(i) Rivista Editore
Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists 2021 Simola, Nicola; Pinna, Annalisa; Frau, Lucia; Costa, Giulia; Marongiu, Jacopo; Parekh, Pathik; Se...rra, Marcello; Morelli, Micaela Springer Nature Switzerland
Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age 2019 Costa, Giulia; Porceddu, Pier Francesca; Serra, Marcello; Casu, Maria Antonietta; Schiano, Valent...ina; Napolitano, Francesco; Pinna, Annalisa; Usiello, Alessandro; Morelli, Micaela INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway 2018 Renaud, Justine; Bassareo, Valentina; Beaulieu, Jimmy; Pinna, Annalisa; Schlich, Michele; Lavoie,... Carole; Murtas, Daniela; Simola, Nicola; Martinoli, Maria-Grazia NEUROBIOLOGY OF AGING
Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia 2018 Pinna, Annalisa; Serra, Marcello; Morelli, Micaela; Simola, Nicola JOURNAL OF NEURAL TRANSMISSION
The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging 2016 Pinna, A; Napolitano, F; Pelosi, B; Di Maio, A; Wardas, J; Casu, Ma; Costa, G; Migliarini, S; Cal...abresi, P; Pasqualetti, M; Morelli, M; Usiello, A MOVEMENT DISORDERS
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 2016 Baranyi, M; Porceddu, Pf; Goloncser, F; Kulcsar, S; Otrokocsi, L; Kittel, A; Pinna, A; Frau, L; H...uleatt, Pb.; Khoo, Ml; Chai, Cll.; Dunkel, P; Matyus, P; Morelli, M; Sperlagh, B MOLECULAR NEURODEGENERATION
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 2016 Pinna, A; Ko, WKD; Costa, G; Tronci, E; Fidalgo, C; Simola, N; Li, Q; Tabrizi, MA; Bezard, E; Car...ta, M; Morelli, M MOVEMENT DISORDERS
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l-DOPA-induced rotational behavior in a rodent model of Parkinson's disease 2015 Fuzzati-Armentero, MT; Cerri, S; Levandis, G; Ambrosi, G; Montepeloso, E; Antoninetti, G; Blandin...i, F; Baqi, Y; Muller, CE; Volpini, R; Costa, G; Simola, N; Pinna, A JOURNAL OF NEUROCHEMISTRY
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A2A receptor antagonists 2014 PINNA A; MORELLI M NEUROTOXICITY RESEARCH
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies 2014 PINNA A; BONAVENTURA J; FARRE D; SANCHEZ M; SIMOLA N; MALLOL J; LLUIS C; COSTA G; BAQI Y; MULLER ...CE; CORTES A; McCORMICK P; CANELA EI; MARTINEZ-PINILLA E; LANCIEGO JL; CASADO' V; ARMENTERO MT; FRANCO R EXPERIMENTAL NEUROLOGY
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 2014 SIMOLA N; PINNA A; FRAU L; MORELLI M Springer
Antiparkinsonian actions and interactions of adenosine antagonists 2014 Morelli, M.; Costa, G.; Pinna, A. PURINERGIC SIGNALLING
Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson’s Disease 2013 PINNA A; SIMOLA N; FRAU L; MORELLI M Springer Science
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward 2012 SIMOLA N; FENU S; COSTA G; PINNA A; PLUMITALLO A; MORELLI M NEUROPHARMACOLOGY
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice 2012 Baiguera, C; Alghisi, M; Pinna, A; Bellucci, A; DE LUCA, Ma; Frau, L; Morelli, M; Ingrassia, R; B...enarese, M; Porrini, V; Pellitteri, M; Bertini, G; Fabene, Pf; Sigala, S; Spillantini, Mg; Liou, Hc; Spano, Pf; Pizzi, M BRAIN
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration 2011 SGADO' P; VIAGGI C; PINNA A; MARRONE C; VAGLINI F; PONTIS S; MERCURI NB; MORELLI M; CORSINI GU NEUROTOXICITY RESEARCH
Farmaci antiparkinsoniani ed attivi in altri disturbi motori 2010 Carta, Annarosa; Pinna, Annalisa; Corsini, Giovanni Umberto; Caramelli, Andrea; Morelli, Micaela Idelson-Gnocchi
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug 2010 Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M NEUROPHARMACOLOGY
Pharmacological therapy of Parkinson's disease: current options and new avenues 2010 Simola, N; Pinna, A; Fenu, S RECENT PATENTS ON CNS DRUG DISCOVERY
Caffeine consumption and changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 2009 SIMOLA N; PINNA A; TRONCI E; SEEMAN P; MORELLI M Nova Science Publishers, Inc.

Questionario e social

Condividi su: